Current and novel therapeutics in the treatment of systemic lupus erythematosus Cagri Yildirim-Toruner, MD, Betty Diamond, MD Journal of Allergy and Clinical Immunology Volume 127, Issue 2, Pages 303-312 (February 2011) DOI: 10.1016/j.jaci.2010.12.1087 Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions
Fig 1 B cell costimulatory molecules and receptors for the survival factors BAFF and APRIL are shown as well as cell surface molecules being targeted therapeutically. The therapeutic agents are identified along with their targets. BCMA, B-cell maturation antigen; CTLA-4, Cytotoxic T lymphocyte–associated antigen 4. Journal of Allergy and Clinical Immunology 2011 127, 303-312DOI: (10.1016/j.jaci.2010.12.1087) Copyright © 2011 American Academy of Allergy, Asthma & Immunology Terms and Conditions